New York, June 23, 2026, 14:01 (EDT)
- Aditxt shares jumped roughly 130% to $0.0442 in Tuesday afternoon trading. The stock touched an intraday high of $0.0592 earlier.
- Takeover Time 2026 LLC reported a 10.9% stake in Aditxt, about 3.42 million shares bought for around $50,000.
- Aditxt shares are up, but the company has raised flags about a possible going-concern issue and has an appeal pending over a potential Nasdaq delisting.
Aditxt Inc. shares jumped more than 100% in heavy trading Tuesday after a new investor said it had taken a stake of over 10% in the Nasdaq-listed health-care stock.
Shares traded up around 130% at $0.0442 in recent action, after swinging from $0.0185 to $0.0592 earlier. More than 3.2 billion shares had changed hands by early afternoon, a huge spike for such a volatile penny stock.
Aditxt is back in play after new ownership filings, not a fresh earnings report or data, caught traders’ attention. According to a Schedule 13D filing—a form investors use when crossing the 5% ownership mark—Takeover Time 2026 LLC reported beneficial ownership of 3,420,439 shares, or 10.9% of the company. Beneficial ownership here means voting or investment control, even if someone else holds the legal title.
Takeover Time disclosed it picked up the shares June 12 in the open market or through brokers, using working capital and spending roughly $50,000 before commissions and fees. The filing names Natasha Ovsepyan as managing member of the Delaware LLC.
The filing didn’t look like a control move. Takeover Time said it bought the shares as an investment and isn’t aiming to change or influence control of Aditxt right now. But it did keep the option open to buy or sell more stock or talk to the company, its management, or other shareholders.
Jonathan Edward Hester filed a separate Schedule 13G showing ownership of 81,592 shares, or 9.9%, of Aditxt. He checked the Rule 13d-1(c) box for passive investors. Schedule 13G is a shorter form for investors not aiming to change control.
The story for Aditxt is still mostly about Ignite Proteomics. Aditxt said earlier this month its wholly owned Ignite unit signed a business-combination deal that puts a roughly $150 million value on Ignite. The plan is for Ignite to spin out as its own public company, with Aditxt staying listed on Nasdaq if it meets compliance rules.
Jeff Busch, who is interim chief executive at Aditxt and also runs Ignite, called the deal “an important milestone” and said it should help unlock value at Ignite. Ignite works in functional proteomics—measuring protein activity in tissue to guide cancer treatment. Business Wire
Aditxt’s surge wasn’t alone on Tuesday. The stock landed on Benzinga’s list of top health-care movers, joined by Atlantic International, Boundless Bio and HeartSciences, but Aditxt’s jump outpaced the rest of biotech. The SPDR S&P Biotech ETF edged up around 1.4%. The Invesco QQQ Trust, which tracks big Nasdaq growth names, dropped about 2.7%.
The filing threw in a note of caution. Takeover Time pointed to Aditxt’s latest reported share count as possibly outdated, so the true ownership might end up higher after checking with either the issuer or the transfer agent. That muddies the headline stake’s clarity.
Aditxt’s cash position adds to the worries. In the March quarter, it reported just $268,852 in cash at March 31 and a net loss of $16.2 million. Revenue has stayed low. The company said these factors raise substantial doubt about its ability to stay in business, warning it might need more funding to keep operating.
Listing risk is active again. Aditxt said Nasdaq staff told it on May 6 its shares faced delisting since the bid price remained under $1, and it wasn’t eligible for another compliance period due to past reverse splits. The company requested a hearing to pause the delisting, but said there’s no guarantee the effort will work.
Nasdaq Trader said Aditxt completed a 1-for-27 reverse stock split effective May 18, assigning a new CUSIP number. A reverse split cuts the share count and boosts the per-share price, but doesn’t address cash burn, dilution risk, or business problems.
For now, this is a filings play. The next dates to watch are any new ownership amendments, updated share counts, what happens at the Nasdaq panel, and filings linked to the Ignite deal. Until then, shares may swing sharply either way.
